Kiniksa Pharmaceuticals International (KNSA) Competitors

$62.58 -1.37 (-2.14%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$62.50 -0.08 (-0.13%)

As of 07/20/2026 07:59 PM Eastern

KNSA vs. GMAB, ASND, BBIO, ELAN, and AXSM

Should you buy Kiniksa Pharmaceuticals International stock or one of its competitors? MarketBeat compares Kiniksa Pharmaceuticals International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kiniksa Pharmaceuticals International include Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

How does Kiniksa Pharmaceuticals International compare to Genmab A/S?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

In the previous week, Genmab A/S had 8 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 10 mentions for Genmab A/S and 2 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 0.82 beat Genmab A/S's score of 0.19 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kiniksa Pharmaceuticals International presently has a consensus price target of $65.14, suggesting a potential upside of 4.10%. Genmab A/S has a consensus price target of $38.21, suggesting a potential upside of 36.92%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Genmab A/S has higher revenue and earnings than Kiniksa Pharmaceuticals International. Genmab A/S is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	7.11	$59.01M	$0.90	69.53
Genmab A/S	$3.72B	4.68	$963M	$1.32	21.14

Kiniksa Pharmaceuticals International has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Genmab A/S has a net margin of 21.05% compared to Kiniksa Pharmaceuticals International's net margin of 9.69%. Genmab A/S's return on equity of 15.34% beat Kiniksa Pharmaceuticals International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Genmab A/S	21.05%	15.34%	8.94%

Summary

Genmab A/S beats Kiniksa Pharmaceuticals International on 9 of the 16 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to Ascendis Pharma A/S?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Kiniksa Pharmaceuticals International has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	7.11	$59.01M	$0.90	69.53
Ascendis Pharma A/S	$865.78M	18.14	-$258M	$8.67	29.04

Ascendis Pharma A/S has a net margin of 57.87% compared to Kiniksa Pharmaceuticals International's net margin of 9.69%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 6 mentions for Ascendis Pharma A/S and 2 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 0.82 beat Ascendis Pharma A/S's score of 0.64 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International currently has a consensus price target of $65.14, suggesting a potential upside of 4.10%. Ascendis Pharma A/S has a consensus price target of $295.67, suggesting a potential upside of 17.44%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Kiniksa Pharmaceuticals International has a beta of 0.07, indicating that its share price is 93% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats Kiniksa Pharmaceuticals International on 10 of the 17 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

BridgeBio Pharma has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market.

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Kiniksa Pharmaceuticals International has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	31.50	-$724.93M	-$3.74	N/A
Kiniksa Pharmaceuticals International	$677.56M	7.11	$59.01M	$0.90	69.53

BridgeBio Pharma presently has a consensus target price of $95.21, suggesting a potential upside of 17.89%. Kiniksa Pharmaceuticals International has a consensus target price of $65.14, suggesting a potential upside of 4.10%. Given BridgeBio Pharma's higher probable upside, equities research analysts clearly believe BridgeBio Pharma is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to BridgeBio Pharma's net margin of -124.42%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

In the previous week, BridgeBio Pharma had 17 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 19 mentions for BridgeBio Pharma and 2 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 0.82 beat BridgeBio Pharma's score of 0.72 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kiniksa Pharmaceuticals International	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kiniksa Pharmaceuticals International beats BridgeBio Pharma on 11 of the 17 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to Elanco Animal Health?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Kiniksa Pharmaceuticals International has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

Kiniksa Pharmaceuticals International has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	7.11	$59.01M	$0.90	69.53
Elanco Animal Health	$4.72B	2.67	-$232M	-$0.50	N/A

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Elanco Animal Health had 6 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 8 mentions for Elanco Animal Health and 2 mentions for Kiniksa Pharmaceuticals International. Elanco Animal Health's average media sentiment score of 1.37 beat Kiniksa Pharmaceuticals International's score of 0.82 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Elanco Animal Health's net margin of -4.95%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Elanco Animal Health	-4.95%	7.42%	3.66%

Kiniksa Pharmaceuticals International presently has a consensus target price of $65.14, suggesting a potential upside of 4.10%. Elanco Animal Health has a consensus target price of $28.55, suggesting a potential upside of 13.39%. Given Elanco Animal Health's higher probable upside, analysts plainly believe Elanco Animal Health is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Summary

Kiniksa Pharmaceuticals International beats Elanco Animal Health on 9 of the 16 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to Axsome Therapeutics?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kiniksa Pharmaceuticals International has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

In the previous week, Axsome Therapeutics had 13 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 15 mentions for Axsome Therapeutics and 2 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 0.82 beat Axsome Therapeutics' score of 0.61 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	4 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Axsome Therapeutics' net margin of -26.59%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Kiniksa Pharmaceuticals International has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	7.11	$59.01M	$0.90	69.53
Axsome Therapeutics	$638.50M	17.86	-$183.17M	-$3.73	N/A

Kiniksa Pharmaceuticals International presently has a consensus target price of $65.14, suggesting a potential upside of 4.10%. Axsome Therapeutics has a consensus target price of $261.48, suggesting a potential upside of 17.97%. Given Axsome Therapeutics' higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95

Summary

Kiniksa Pharmaceuticals International beats Axsome Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Kiniksa Pharmaceuticals International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KNSA vs. The Competition

Export

Metric	Kiniksa Pharmaceuticals International	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.92B	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	69.53	20.49	27.07	23.94
Price / Sales	7.11	300.32	515.45	90.30
Price / Cash	80.57	60.31	26.68	47.25
Price / Book	8.41	7.92	10.42	6.14
Net Income	$59.01M	$23.81M	$3.60B	$331.74M
7 Day Performance	0.97%	-1.09%	-1.26%	-1.81%
1 Month Performance	13.55%	2.56%	1.07%	-1.44%
1 Year Performance	120.20%	42.16%	23.61%	16.33%

Kiniksa Pharmaceuticals International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KNSA Kiniksa Pharmaceuticals International	3.0012 of 5 stars	$62.58 -2.1%	$65.14 +4.1%	+115.6%	$4.92B	$677.56M	69.53	220	Upcoming Earnings
GMAB Genmab A/S	4.5289 of 5 stars	$28.98 -0.3%	$38.21 +31.9%	+27.6%	$18.07B	$3.90B	21.95	3,029	Positive News
ASND Ascendis Pharma A/S	4.4398 of 5 stars	$259.80 -3.3%	$295.67 +13.8%	+48.2%	$16.21B	$814.57M	29.97	1,189	Positive News Analyst Downgrade
BBIO BridgeBio Pharma	3.5907 of 5 stars	$80.30 -2.9%	$95.21 +18.6%	+73.6%	$15.73B	$579.96M	N/A	400
ELAN Elanco Animal Health	3.9173 of 5 stars	$25.95 +1.6%	$28.55 +10.0%	+70.3%	$12.96B	$4.89B	N/A	9,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KNSA) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kiniksa Pharmaceuticals International (KNSA) Competitors

KNSA vs. GMAB, ASND, BBIO, ELAN, and AXSM

How does Kiniksa Pharmaceuticals International compare to Genmab A/S?

Summary

How does Kiniksa Pharmaceuticals International compare to Ascendis Pharma A/S?

Summary

How does Kiniksa Pharmaceuticals International compare to BridgeBio Pharma?

Summary

How does Kiniksa Pharmaceuticals International compare to Elanco Animal Health?

Summary

How does Kiniksa Pharmaceuticals International compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KNSA vs. The Competition

Kiniksa Pharmaceuticals International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kiniksa Pharmaceuticals International (KNSA) Competitors

KNSA vs. GMAB, ASND, BBIO, ELAN, and AXSM

How does Kiniksa Pharmaceuticals International compare to Genmab A/S?

Does the media prefer KNSA or GMAB?

Do analysts recommend KNSA or GMAB?

Which has better earnings & valuation, KNSA or GMAB?

Which has more risk & volatility, KNSA or GMAB?

Do insiders and institutionals hold more shares of KNSA or GMAB?

Is KNSA or GMAB more profitable?

Summary

How does Kiniksa Pharmaceuticals International compare to Ascendis Pharma A/S?

Which has preferable valuation & earnings, KNSA or ASND?

Is KNSA or ASND more profitable?

Does the media prefer KNSA or ASND?

Do analysts rate KNSA or ASND?

Do institutionals & insiders hold more shares of KNSA or ASND?

Which has more risk and volatility, KNSA or ASND?

Summary

How does Kiniksa Pharmaceuticals International compare to BridgeBio Pharma?

Which has more risk & volatility, BBIO or KNSA?

Do institutionals and insiders hold more shares of BBIO or KNSA?

Which has preferable earnings & valuation, BBIO or KNSA?

Do analysts recommend BBIO or KNSA?

Is BBIO or KNSA more profitable?

Does the media refer more to BBIO or KNSA?

Summary

How does Kiniksa Pharmaceuticals International compare to Elanco Animal Health?

Which has more risk and volatility, KNSA or ELAN?

Which has preferable earnings & valuation, KNSA or ELAN?

Do institutionals & insiders hold more shares of KNSA or ELAN?

Does the media favor KNSA or ELAN?

Is KNSA or ELAN more profitable?

Do analysts recommend KNSA or ELAN?

Summary

How does Kiniksa Pharmaceuticals International compare to Axsome Therapeutics?

Do insiders and institutionals have more ownership in KNSA or AXSM?

Which has more volatility and risk, KNSA or AXSM?

Does the media favor KNSA or AXSM?

Is KNSA or AXSM more profitable?

Which has stronger earnings & valuation, KNSA or AXSM?

Do analysts rate KNSA or AXSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KNSA vs. The Competition

Kiniksa Pharmaceuticals International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools